Endometriosis therapy - Bayer/Evotec

Drug Profile

Endometriosis therapy - Bayer/Evotec

Alternative Names: Second endometriosis candidate - Bayer/Evotec

Latest Information Update: 10 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer; Evotec AG
  • Class Analgesics; Anti-inflammatories
  • Mechanism of Action Inflammation mediator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Endometriosis

Most Recent Events

  • 24 Jul 2017 Phase-I clinical trials in Endometriosis in Germany (unspecified route)
  • 24 Jul 2017 Evotec and Bayer extend collaboration for Endometriosis therapeutics until 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top